Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
Add more filters










Publication year range
1.
Neurology ; 59(12): 1881-8, 2002 Dec 24.
Article in English | MEDLINE | ID: mdl-12499478

ABSTRACT

OBJECTIVE: To determine the molecular basis of a disabling congenital myasthenic syndrome (CMS) observed in two related and one unrelated Arab kinship. BACKGROUND: CMS can arise from defects in presynaptic, synaptic basal lamina-associated, or postsynaptic proteins. Most CMS are postsynaptic, and most reside in the AChR epsilon subunit; only two mutations have been reported in the AChR delta subunit to date. METHODS: Cytochemistry, electron microscopy, alpha-bungarotoxin binding studies, microelectrode and patch-clamp recordings, mutation analysis, mutagenesis, and expression studies in human embryonic kidney cells were employed. RESULTS: Endplate studies showed AChR deficiency, fast decaying, low-amplitude endplate currents, and abnormally brief channel opening events. Mutation analysis revealed a novel homozygous missense mutation (deltaP250Q) of the penultimate proline in the first transmembrane domain (TMD1) of the AChR delta subunit. Expression studies indicate that deltaP250Q (1) hinders delta/alpha subunit association during early AChR assembly; (2) hinders opening of the doubly occupied closed receptor (A(2)R); and (3) speeds the dissociation of acetylcholine from A(2)R. Mutagenesis studies indicate that deltaP250L also has fast-channel effects, whereas epsilon P245L and epsilon P245Q, identical mutations of the corresponding proline in the epsilon subunit, have mild slow-channel effects. CONCLUSIONS: deltaP250Q represents the third mutation observed in the AChR delta subunit. The severe phenotype caused by deltaP250Q is attributed to endplate AChR deficiency, fast decay of the synaptic response, and lack of compensatory factors. That the penultimate prolines in TMD1 of the delta and epsilon subunits exert a reciprocal regulatory effect on the length of the channel opening bursts reveals an unexpected functional asymmetry between the two subunits.


Subject(s)
Myasthenic Syndromes, Congenital/genetics , Receptors, Cholinergic/genetics , Acetylcholine/metabolism , Acetylcholinesterase/metabolism , Adolescent , Adult , Amino Acid Sequence , Amino Acid Substitution/genetics , Bungarotoxins/metabolism , Cell Line , Child , DNA Mutational Analysis , Electrophysiology , Female , Humans , Kinetics , Male , Membrane Potentials/physiology , Molecular Sequence Data , Motor Endplate/pathology , Motor Endplate/physiology , Muscle, Skeletal/physiopathology , Mutation, Missense/genetics , Myasthenic Syndromes, Congenital/metabolism , Patch-Clamp Techniques , Proline/metabolism , Receptors, Cholinergic/metabolism
2.
Proc Natl Acad Sci U S A ; 98(4): 2017-22, 2001 Feb 13.
Article in English | MEDLINE | ID: mdl-11172068

ABSTRACT

Choline acetyltransferase (ChAT; EC ) catalyzes the reversible synthesis of acetylcholine (ACh) from acetyl CoA and choline at cholinergic synapses. Mutations in genes encoding ChAT affecting motility exist in Caenorhabditis elegans and Drosophila, but no CHAT mutations have been observed in humans to date. Here we report that mutations in CHAT cause a congenital myasthenic syndrome associated with frequently fatal episodes of apnea (CMS-EA). Studies of the neuromuscular junction in this disease show a stimulation-dependent decrease of the amplitude of the miniature endplate potential and no deficiency of the ACh receptor. These findings point to a defect in ACh resynthesis or vesicular filling and to CHAT as one of the candidate genes. Direct sequencing of CHAT reveals 10 recessive mutations in five patients with CMS-EA. One mutation (523insCC) is a frameshifting null mutation. Three mutations (I305T, R420C, and E441K) markedly reduce ChAT expression in COS cells. Kinetic studies of nine bacterially expressed ChAT mutants demonstrate that one mutant (E441K) lacks catalytic activity, and eight mutants (L210P, P211A, I305T, R420C, R482G, S498L, V506L, and R560H) have significantly impaired catalytic efficiencies.


Subject(s)
Apnea/complications , Choline O-Acetyltransferase/genetics , Mutation , Myasthenic Syndromes, Congenital/enzymology , Adult , Amino Acid Sequence , Animals , Bungarotoxins/metabolism , COS Cells , Child , Child, Preschool , Chlorocebus aethiops , Choline O-Acetyltransferase/biosynthesis , Escherichia coli , Female , Humans , Kinetics , Male , Mice , Molecular Sequence Data , Motor Endplate/metabolism , Myasthenic Syndromes, Congenital/complications , Myasthenic Syndromes, Congenital/genetics , Rats , Sequence Homology, Amino Acid , Spinal Cord , Swine
3.
J Gen Physiol ; 116(3): 449-62, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10962020

ABSTRACT

We describe the genetic and kinetic defects in a congenital myasthenic syndrome due to the mutation epsilonA411P in the amphipathic helix of the acetylcholine receptor (AChR) epsilon subunit. Myasthenic patients from three unrelated families are either homozygous for epsilonA411P or are heterozygous and harbor a null mutation in the second epsilon allele, indicating that epsilonA411P is recessive. We expressed human AChRs containing wild-type or A411P epsilon subunits in 293HEK cells, recorded single channel currents at high bandwidth, and determined microscopic rate constants for individual channels using hidden Markov modeling. For individual wild-type and mutant channels, each rate constant distributes as a Gaussian function, but the spread in the distributions for channel opening and closing rate constants is greatly expanded by epsilonA411P. Prolines engineered into positions flanking residue 411 of the epsilon subunit greatly increase the range of activation kinetics similar to epsilonA411P, whereas prolines engineered into positions equivalent to epsilonA411 in beta and delta subunits are without effect. Thus, the amphipathic helix of the epsilon subunit stabilizes the channel, minimizing the number and range of kinetic modes accessible to individual AChRs. The findings suggest that analogous stabilizing structures are present in other ion channels, and possibly allosteric proteins in general, and that they evolved to maintain uniformity of activation episodes. The findings further suggest that the fundamental gating mechanism of the AChR channel can be explained by a corrugated energy landscape superimposed on a steeply sloped energy well.


Subject(s)
Myasthenic Syndromes, Congenital/genetics , Myasthenic Syndromes, Congenital/metabolism , Point Mutation , Receptors, Cholinergic/genetics , Receptors, Cholinergic/metabolism , Cell Line , Humans , Ion Channel Gating , Kinetics , Markov Chains , Models, Biological , Patch-Clamp Techniques , Protein Structure, Secondary , Receptors, Cholinergic/chemistry , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism
4.
Ann Neurol ; 47(2): 162-70, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10665486

ABSTRACT

The end-plate species of acetylcholinesterase (AChE) is an asymmetric enzyme consisting of a collagenic tail subunit composed of three collagenic strands (ColQ), each attached to a tetramer of the T isoform of the catalytic subunit (AChE(T)) via a proline-rich attachment domain. The principal function of the tail subunit is to anchor asymmetric AChE in the synaptic basal lamina. Human end-plate AChE deficiency was recently shown to be caused by mutations in COLQ. We here report nine novel COLQ mutations in 7 patients with end-plate AChE deficiency. We examine the effects of the mutations on the assembly of asymmetric AChE by coexpressing each genetically engineered COLQ mutant with ACHE(T) in COS cells. We classify the newly recognized and previously reported COLQ mutations into four classes according to their position in ColQ and their effect on AChE expression. We find that missense mutations in the proline-rich attachment domain abrogate attachment of catalytic subunits, that truncation mutations in the ColQ collagen domain prevent the assembly of asymmetric AChE, that hydrophobic missense residues in the C-terminal domain prevent triple helical assembly of the ColQ collagen domain, and that other mutations in the C-terminal region produce asymmetric species of AChE that are likely insertion incompetent.


Subject(s)
Acetylcholinesterase/deficiency , Acetylcholinesterase/genetics , Collagen , Motor Endplate/enzymology , Muscle Proteins , Mutation , Adolescent , Adult , Animals , COS Cells , DNA Mutational Analysis , Female , Gene Expression , Humans , Infant , Male , Microscopy, Electron , Motor Endplate/pathology , Mutation/genetics , Mutation, Missense
5.
J Clin Invest ; 104(10): 1403-10, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10562302

ABSTRACT

We describe a severe postsynaptic congenital myasthenic syndrome with marked endplate acetylcholine receptor (AChR) deficiency caused by 2 heteroallelic mutations in the beta subunit gene. One mutation causes skipping of exon 8, truncating the beta subunit before its M1 transmembrane domain, and abolishing surface expression of pentameric AChR. The other mutation, a 3-codon deletion (beta426delEQE) in the long cytoplasmic loop between the M3 and M4 domains, curtails but does not abolish expression. By coexpressing beta426delEQE with combinations of wild-type subunits in 293 HEK cells, we demonstrate that beta426delEQE impairs AChR assembly by disrupting a specific interaction between beta and delta subunits. Studies with related deletion and missense mutants indicate that secondary structure in this region of the beta subunit is crucial for interaction with the delta subunit. The findings imply that the mutated residues are positioned at the interface between beta and delta subunits and demonstrate contribution of this local region of the long cytoplasmic loop to AChR assembly.


Subject(s)
Muscle, Skeletal/metabolism , Myasthenia Gravis, Neonatal/genetics , Receptors, Cholinergic/genetics , Sequence Deletion , Acetylcholinesterase/metabolism , Alleles , Amino Acid Sequence , Animals , Child , Codon , Exons , Female , Humans , Macromolecular Substances , Male , Molecular Sequence Data , Motor Endplate/pathology , Motor Endplate/physiology , Muscle, Skeletal/pathology , Muscle, Skeletal/physiopathology , Myasthenia Gravis, Neonatal/pathology , Myasthenia Gravis, Neonatal/physiopathology , Nuclear Family , Pedigree , Protein Structure, Secondary , Receptors, Cholinergic/chemistry , Receptors, Cholinergic/metabolism , Reference Values , Sequence Alignment , Sequence Homology, Amino Acid
6.
Am J Hum Genet ; 65(3): 635-44, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10441569

ABSTRACT

Congenital end-plate acetylcholinesterase (AChE) deficiency (CEAD), the cause of a disabling myasthenic syndrome, arises from defects in the COLQ gene, which encodes the AChE triple-helical collagenlike-tail subunit that anchors catalytic subunits of AChE to the synaptic basal lamina. Here we describe a patient with CEAD with a nonsense mutation (R315X) and a splice-donor-site mutation at position +3 of intron 16 (IVS16+3A-->G) of COLQ. Because both A and G are consensus nucleotides at the +3 position of splice-donor sites, we constructed a minigene that spans exons 15-17 and harbors IVS16+3A-->G for expression in COS cells. We found that the mutation causes skipping of exon 16. The mutant splice-donor site of intron 16 harbors five discordant nucleotides (at -3, -2, +3, +4, and +6) that do not base-pair with U1 small-nuclear RNA (snRNA), the molecule responsible for splice-donor-site recognition. Versions of the minigene harboring, at either +4 or +6, nucleotides complementary to U1 snRNA restore normal splicing. Analysis of 1,801 native splice-donor sites reveals that presence of a G nucleotide at +3 is associated with preferential usage, at positions +4 to +6, of nucleotides concordant to U1 snRNA. Analysis of 11 disease-associated IVS+3A-->G mutations indicates that, on average, two of three nucleotides at positions +4 to +6 fail to base-pair, and that the nucleotide at +4 never base-pairs, with U1 snRNA. We conclude that, with G at +3, normal splicing generally depends on the concordance that residues at +4 to +6 have with U1 snRNA, but other cis-acting elements may also be important in assuring the fidelity of splicing.


Subject(s)
Acetylcholinesterase/deficiency , Acetylcholinesterase/genetics , Alternative Splicing/genetics , Collagen , Motor Endplate/enzymology , Muscle Proteins , Mutation , Acetylcholinesterase/metabolism , Animals , Base Pairing , Base Sequence , COS Cells , DNA Mutational Analysis , Exons/genetics , Female , Gene Expression , Humans , Introns/genetics , Male , Middle Aged , Motor Endplate/physiopathology , Pedigree , RNA, Messenger/analysis , RNA, Messenger/genetics , RNA, Small Nuclear/genetics , Reverse Transcriptase Polymerase Chain Reaction , Transfection
7.
Ann Neurol ; 44(2): 234-41, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9708546

ABSTRACT

We report and functionally characterize five new mutations of the acetylcholine receptor (AChR) in 11 Turkish patients with recessive congenital myasthenic syndromes (CMS) belonging to six families. All mutations are in the epsilon-subunit gene. Parental consanguinity is present in three families. The disease cosegregates with homozygous mutations in five families and with two different heteroallelic mutations in one family. Four mutations are frameshifting, predicting truncation of the epsilon subunit, and one occurs at a splice donor site. Expression of each frameshifting mutation and the likely transcripts of the splice-site mutation in human embryonic kidney 293 cells shows that each mutation is a null mutation. The findings support the notion that loss-of-function mutations of the acetylcholine receptor causing CMS are concentrated in the epsilon subunit, and that such mutations are a frequent cause of CMS.


Subject(s)
Myasthenia Gravis/ethnology , Myasthenia Gravis/genetics , Receptors, Cholinergic/genetics , Base Sequence , DNA/analysis , Female , Frameshift Mutation , Humans , Male , Molecular Sequence Data , Mutation , Pedigree , Polymorphism, Restriction Fragment Length , Syndrome , Turkey
10.
Neuroreport ; 9(8): 1907-11, 1998 Jun 01.
Article in English | MEDLINE | ID: mdl-9665624

ABSTRACT

Quinidine is a long-lived open-channel blocker of the wild-type endplate acetylcholine receptor (AChR). To test the hypothesis that quinidine can normalize the prolonged channel opening events of slow-channel mutants of human AChR, we expressed wild-type AChR and five well characterized slow-channel mutants of AChR in HEK 293 cells and monitored the effects of quinidine on acetylcholine-induced channel currents. Quinidine shortens the longest component of channel opening burst (tau3b) of both wild-type and mutant AChRs in a concentration-dependent manner, and 5 microM quinidine reduces tau3b of the mutant AChRs to that of wild-type AChRs in the absence of quinidine. Because this concentration of quinidine is attainable in clinical practice, the findings predict a therapeutic effect for quinidine in the slow-channel congenital myasthenic syndrome.


Subject(s)
Cholinergic Antagonists/pharmacology , Quinidine/pharmacology , Receptors, Cholinergic/genetics , Humans , Linear Models , Logistic Models , Membrane Potentials/drug effects , Mutation , Patch-Clamp Techniques
11.
Neuron ; 20(3): 575-88, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9539130

ABSTRACT

We describe the genetic and kinetic defects in a congenital myasthenic syndrome caused by heteroallelic mutations of the acetylcholine receptor (AChR) epsilon subunit gene. The mutations are an in-frame duplication of six residues in the long cytoplasmic loop (epsilon1254ins18) and a cysteine-loop null mutation (epsilonC128S). The epsilon1254 ins18 mutation causes mode switching in the kinetics of receptor activation in which three modes activate slowly and inactivate rapidly. The epsilon1245ins18-AChR at the endplate shows abnormally brief activation episodes during steady state agonist application and appears electrically silent during the synaptic response to acetylcholine. The phenotypic consequences are endplate AChR deficiency, simplification of the postsynaptic region, and compensatory expression of fetal AChR that restores electrical activity at the endplate and rescues the phenotype.


Subject(s)
Ion Channel Gating/genetics , Myasthenia Gravis/genetics , Point Mutation , Receptors, Cholinergic/genetics , Acetylcholine/pharmacology , Adult , Amino Acid Sequence , Base Sequence , Cells, Cultured , DNA Mutational Analysis , Dose-Response Relationship, Drug , Family Health , Female , Gene Expression , Humans , Intercostal Muscles/chemistry , Intercostal Muscles/physiology , Ion Channel Gating/drug effects , Kidney/cytology , Kinetics , Male , Microscopy, Electron , Motor Endplate/chemistry , Motor Endplate/physiology , Motor Endplate/ultrastructure , Myasthenia Gravis/physiopathology , Patch-Clamp Techniques , Protein Structure, Tertiary , Receptors, Cholinergic/chemistry , Transfection
12.
Hum Mol Genet ; 6(5): 753-66, 1997 May.
Article in English | MEDLINE | ID: mdl-9158150

ABSTRACT

We describe and functionally characterize six mutations of the acetylcholine receptor (AChR) epsilon subunit gene in three congenital myasthenic syndrome patients. Endplate studies demonstrated severe endplate AChR deficiency, dispersed endplate regions and well preserved junctional folds in all three patients. Electrophysiologic studies were consistent with expression of the fetal gamma-AChR at the endplates in one patient, prolongation of some channel events in another and gamma-AChR expression as well as some shorter than normal channel events in still another. Genetic analysis revealed two recessive and heteroallelic epsilon subunit gene mutations in each patient. One mutation in each (epsilonC190T [epsilon R64X], epsilon 127ins5 and epsilon 553del 7) generates a nonsense codon that predicts truncation of the epsilon subunit in its N-terminal, extracellular domain; and one mutation in each generates a missense codon (epsilon R147L, epsilon P245L and epsilon R311W). None of the mutations was detected in 100 controls. Expression studies in HEK cells indicate that the three nonsense mutations are null mutations and that surface expression of AChRs harboring the missense mutations is significantly reduced. Kinetic analysis of AChRs harboring the missense mutations show that epsilon R147L is kinetically benign, epsilon P245L prolongs burst open duration 2-fold by slowing the rate of channel closing and epsilon R311W shortens burst duration 2-fold by slowing the rate of channel opening and speeding the rate of ACh dissociation. The modest changes in activation kinetics are probably overshadowed by reduced expression of the missense mutations. The consequences of the endplate AChR deficiency are mitigated by persistent expression of gamma-AChR, changes in the release of transmitter quanta and appearance of multiple endplate regions on the muscle fiber.


Subject(s)
Motor Endplate/physiology , Mutation , Myasthenia Gravis/genetics , Receptors, Cholinergic/genetics , Receptors, Cholinergic/metabolism , Acetylcholine/pharmacology , Action Potentials , Adult , Alleles , Amino Acid Sequence , Animals , Binding, Competitive , Child , Child, Preschool , Electrophysiology , Female , Fibroblasts/drug effects , Fibroblasts/metabolism , Humans , Infant , Infant, Newborn , Kinetics , Male , Mice , Molecular Sequence Data , Motor Endplate/metabolism , Motor Endplate/pathology , Myasthenia Gravis/congenital , Patch-Clamp Techniques , Rats , Receptors, Cholinergic/deficiency , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Sequence Alignment , Sequence Homology, Amino Acid , Transfection
13.
Hum Mol Genet ; 5(9): 1217-27, 1996 Sep.
Article in English | MEDLINE | ID: mdl-8872460

ABSTRACT

Mutations in genes encoding the epsilon, delta, beta and alpha subunits of the end plate acetylcholine (ACh) receptor (AChR) are described and functionally characterized in three slow-channel congenital myasthenic syndrome patients. All three had prolonged end plate currents and AChR channel opening episodes and an end plate myopathy with loss of AChR from degenerating junctional folds. Genetic analysis revealed heterozygous mutations: epsilon L269F and delta Q267E in Patient 1, beta V266M in Patient 2, and alpha N217K in Patient 3 that were not detected in 100 normal controls. Patients 1 and 2 have no similarly affected relatives; in Patient 3, the mutation cosegregates with the disease in three generations. epsilon L269F, delta Q267E and beta V266M occur in the second and alpha N217K in the first transmembrane domain of AChR subunits; all have been postulated to contribute to the lining of the upper half of the channel lumen and all but delta Q267E are positioned toward the channel lumen, and introduce an enlarged side chain. Expression studies in HEK cells indicate that all of the mutations express normal amounts of AChR. epsilon L269F, beta V266M, and alpha N217K slow the rate of channel closure in the presence of ACh and increase apparent affinity for ACh; epsilon L269F and alpha N217K enhance desensitization, and epsilon L269F and beta V266M cause pathologic channel openings in the absence of ACh, rendering the channel leaky, delta Q267E has none of these effects and is therefore a rare polymorphism or a benign mutation. The end plate myopathy stems from cationic overloading of the postsynaptic region. The safety margin of neuromuscular transmission is compromised by AChR loss from the junctional folds and by a depolarization block owing to temporal summation of prolonged end plate potentials at physiologic rates of stimulation.


Subject(s)
Genetic Heterogeneity , Myasthenia Gravis/genetics , Receptors, Cholinergic/genetics , Adolescent , Amino Acid Sequence , Humans , Male , Molecular Sequence Data , Mutation , Myasthenia Gravis/physiopathology , Patch-Clamp Techniques , Polymorphism, Genetic , Polymorphism, Single-Stranded Conformational , Receptors, Cholinergic/physiology , Syndrome
14.
Neuron ; 17(1): 157-70, 1996 Jul.
Article in English | MEDLINE | ID: mdl-8755487

ABSTRACT

We describe the genetic and kinetic defects for a low-affinity fast channel disease of the acetylcholine receptor (AChR) that causes a myasthenic syndrome. In two unrelated patients with very small miniature end plate (EP) potentials, but with normal EP AChR density and normal EP ultrastructure, patch-clamp studies demonstrated infrequent AChR channel events, diminished channel reopenings during ACh occupancy, and resistance to desensitization by ACh. Each patient had two heteroallelic AChR epsilon subunit gene mutations: a common epsilon P121L mutation, a signal peptide mutation (epsilon G-8R) (patient 1), and a glycosylation consensus site mutation (epsilon S143L) (patient 2). AChR expression in HEK fibroblasts was normal with epsilon P121L but was markedly reduced with the other mutations. Therefore, epsilon P121L defines the clinical phenotype. Studies of the engineered epsilon P121L AChR revealed a markedly decreased rate of channel opening, little change in affinity of the resting state for ACh, but reduced affinity of the open channel and desensitized states.


Subject(s)
Lambert-Eaton Myasthenic Syndrome/genetics , Mutation , Receptors, Cholinergic/genetics , Acetylcholine/metabolism , Amino Acid Sequence , Base Sequence , Binding, Competitive , Cell Line , Electrophysiology , Humans , Kinetics , Lambert-Eaton Myasthenic Syndrome/congenital , Lambert-Eaton Myasthenic Syndrome/physiopathology , Molecular Probes/genetics , Molecular Sequence Data , Patch-Clamp Techniques , Receptors, Cholinergic/metabolism , Receptors, Cholinergic/physiology
15.
J Neuroimmunol ; 63(1): 9-16, 1995 Dec.
Article in English | MEDLINE | ID: mdl-8557829

ABSTRACT

We investigated the profiles of cytokine mRNA expression in muscle in 15 cases of inflammatory myopathy (IM) (5 each of polymyositis, inclusion body myositis, and dermatomyositis) and in 10 controls (5 of Duchenne dystrophy and 5 non-weak subjects). Expressions of the predominantly T cell-derived cytokines (interleukin (IL)-2, IL-4, IL-5, and interferon-gamma (IFN-gamma), of the predominantly macrophage-derived cytokines (IL-1, IL-6, and tumor necrosis factor-alpha (TNF-alpha)), as well as cytokines that can be of either T cell or macrophage origin (granulocyte-macrophage colony stimulating factor (GM-CSF) and transforming growth factor beta 1 (TGF-beta 1) and TGF-beta 2), were monitored by the reverse transcriptase-PCR method. The expression of T cell cytokine mRNAs for IL-2, IL-5, and IFN-gamma was generally weak or inconsistent. IL-4 mRNA expression was consistently moderate to strong in polymyositis but generally weak or absent in the other IMs. The expression of macrophage cytokine mRNAs for IL-1 alpha and IL-1 beta was weak or absent in all cases. Variable TNF-alpha mRNA expression was observed in 12 of 15 IM cases and faint or weak expression in 5 of 10 controls. Very strong GM-CSF expression was detected, but only on boosted PCR, in 12 of 15 cases of IM but in none of the controls. IL-6 was expressed only weakly or inconsistently. In contrast to the variable expression of several of the above mentioned cytokine mRNAs, all IM specimens strongly expressed TGF-beta 1 mRNA and 12 of 15 strongly expressed TGF-beta 2 mRNA. Thus, with the exception of IL-4 expression in polymyositis, a similar pattern of cytokine mRNA expression exists in the different types of IMs. Moreover, this pattern resembles that detected in non-weak and DD controls, although expression is generally weaker in the non-weak controls. The findings suggest that in IM muscle a sustained secretion of cytokines by T cells or of IL-1 by macrophages is not a prerequisite for operation of the immune effector response and that muscle may not be the site of ongoing sensitization.


Subject(s)
Cytokines/genetics , Muscles/metabolism , Muscular Dystrophies/metabolism , Myositis/metabolism , RNA, Messenger/analysis , Actins/genetics , Base Sequence , Humans , Interferon-gamma/genetics , Interleukins/genetics , Molecular Sequence Data , Transforming Growth Factor beta/genetics , Tumor Necrosis Factor-alpha/genetics
16.
Proc Natl Acad Sci U S A ; 92(3): 758-62, 1995 Jan 31.
Article in English | MEDLINE | ID: mdl-7531341

ABSTRACT

In a congenital myasthenic syndrome with a severe endplate myopathy, patch-clamp studies revealed markedly prolonged acetylcholine receptor (AChR) channel openings. Molecular genetic analysis of AChR subunit genes demonstrated a heterozygous adenosine-to-cytosine transversion at nucleotide 790 in exon 8 of the epsilon-subunit gene, predicting substitution of proline for threonine at codon 264 and no other mutations in the entire coding sequences of genes encoding the alpha, beta, delta, and epsilon subunits. Genetically engineered mutant AChR expressed in a human embryonic kidney fibroblast cell line also exhibited markedly prolonged openings in the presence of agonist and even opened in its absence. The Thr-264-->Pro mutation in the epsilon subunit involves a highly conserved residue in the M2 domain lining the channel pore and is likely to disrupt the putative M2 alpha-helix. Our findings indicate that a single mutation at a critical site can greatly alter AChR channel kinetics, leading to a congenital myasthenic syndrome. This observation raises the possibility that mutations involving subunits of other ligand-gated channels may also exist and be the basis of various other neurologic or psychiatric disorders.


Subject(s)
Ion Channels/metabolism , Neuromuscular Diseases/metabolism , Receptors, Cholinergic/genetics , Receptors, Cholinergic/metabolism , Acetylcholine/physiology , Adolescent , Amino Acid Sequence , Base Sequence , Cell Line , DNA Mutational Analysis , Exons/genetics , Female , Fibroblasts , Humans , Intercostal Muscles , Molecular Sequence Data , Motor Endplate/metabolism , Neuromuscular Diseases/congenital , Neuromuscular Diseases/genetics , Patch-Clamp Techniques , Point Mutation , Polymorphism, Single-Stranded Conformational , Syndrome
18.
Acta Neuropathol ; 86(2): 206-11, 1993.
Article in English | MEDLINE | ID: mdl-8213077

ABSTRACT

We describe a woman with paraneoplastic cerebellar degeneration associated with para-ovarian adenocarcinoma, who had a circulating antibody with a corresponding antigen not only in cerebellar Purkinje cells but also in neurons located in the molecular layer of the human and rat cerebellum. The antigen was also present in neurons in the cerebral cortex, brain stem, anterior horn cells, dorsal root ganglia, intestinal autonomic neurons, retinal ganglion cells, Schwann cells of the peripheral nerve and epithelial cells of the renal glomerulus in rats. Immunoelectron microscopy revealed immunoprecipitates in the smooth and rough endoplasmic reticulum and polyribosomes in human and rat cerebellar Purkinje cells and other neuronal cell bodies as well as Schwann cells of the peripheral nerve. Even though patients with this disorder manifest primarily with cerebellar and some extracerebellar signs, the antigen also exists in many neurons other than cerebellar Purkinje cells and even in non-neuronal cells. The clinicopathologic significance of the observed immunologic reaction in diverse neurons remains to be determined.


Subject(s)
Antibodies, Neoplasm/immunology , Cerebellar Diseases/pathology , Neurons/immunology , Paraneoplastic Syndromes/pathology , Adenocarcinoma/complications , Adenocarcinoma/pathology , Adenocarcinoma/secondary , Aged , Aged, 80 and over , Animals , Antibodies, Neoplasm/analysis , Blotting, Western , Cerebellar Diseases/complications , Cerebellar Neoplasms/complications , Cerebellar Neoplasms/pathology , Cerebellar Neoplasms/secondary , Cerebellum/ultrastructure , Cerebral Cortex/ultrastructure , Female , Humans , Immunohistochemistry , Microscopy, Immunoelectron , Middle Aged , Nerve Tissue Proteins/immunology , Nerve Tissue Proteins/metabolism , Neurons/ultrastructure , Ovarian Neoplasms/pathology , Paraneoplastic Syndromes/immunology , Purkinje Cells/immunology , Purkinje Cells/ultrastructure , Rats , Rats, Wistar , Spinal Cord/pathology , Subcellular Fractions/metabolism
19.
Acta Neuropathol ; 80(5): 499-505, 1990.
Article in English | MEDLINE | ID: mdl-2251907

ABSTRACT

Differential vulnerability of the major components of microtubules was examined in ischemic gerbil brains by a light microscopic, immunohistochemical method using monoclonal antibodies for microtubule-associated protein (MAP) 1A and MAP2, polyclonal antibody for MAP1 and 2 as well as monoclonal antibody for alpha-tubulin. Progressive cerebral ischemia during unilateral carotid occlusion for 5, 15 and 120 min and reperfusion for 3, 12 and 48 h following bilateral carotid occlusion for 10 min were studied. Ischemic lesions in the subiculum-CA1 region were visualized by all antibodies after ischemia for 5 min but the antibody for alpha-tubulin was less sensitive. The antibody for alpha-tubulin was also less sensitive than antibodies for MAPs for detection of early postischemic lesions. Differential sensitivity was also observed in the cerebral cortex and other brain regions. Microtubules in myelinated axons were more stable than those in dendrites. The observed loss of immunohistochemical reactivities for MAPs and alpha-tubulin may have been caused by activation of calcium-dependent proteolytic enzymes such as calpains. The discrepancy between MAPs and alpha-tubulin could be due to differences in affinities or topographic distributions of these proteins within microtubules.


Subject(s)
Brain Ischemia/metabolism , Microtubules/metabolism , Animals , Gerbillinae , Immunoenzyme Techniques , Microtubule-Associated Proteins/metabolism , Reperfusion , Tubulin/metabolism
20.
Stroke ; 19(12): 1526-34, 1988 Dec.
Article in English | MEDLINE | ID: mdl-3201512

ABSTRACT

We investigated progression and recovery of neuronal damage during and after global cerebral ischemia in gerbils after bilateral occlusion of the common carotid arteries, using the immunohistochemical method (reaction for tubulin and creatine kinase BB-isoenzyme). The earliest, but reversible, ischemic lesions occurred after 3 minutes' ischemia in the subiculum-CA1 and CA2 regions of the hippocampus. The lesions became irreversible after 4 minutes' ischemia. The ischemic and postischemic lesions in the cerebral cortex, thalamus, and caudoputamen were partially or completely reversible if the ischemic period was 5 minutes, whereas delayed degeneration occurred in the pyramidal cells of the medial CA1 region after reperfusion for 48 hours (delayed neuronal death). After 10 minutes' ischemia and subsequent reperfusion, delayed neuronal death extended from the medial to the lateral CA1 region; the ischemic and postischemic lesions in the cerebral cortex, thalamus, and caudoputamen also expanded during reperfusion. Our investigation demonstrates that selective vulnerability existed in global cerebral ischemia as in incomplete or regional ischemia and suggests that neurons in many areas of the brain possessed the potential for recovery, progressive deterioration, and even delayed neuronal death depending on the severity and duration of cerebral ischemia.


Subject(s)
Arterial Occlusive Diseases/pathology , Brain Ischemia/pathology , Carotid Artery Diseases/pathology , Animals , Arterial Occlusive Diseases/physiopathology , Brain Ischemia/physiopathology , Carotid Artery Diseases/physiopathology , Cell Survival , Cerebral Cortex/pathology , Female , Gerbillinae , Hippocampus/pathology , Immunohistochemistry , Male , Putamen/pathology , Reperfusion , Thalamus/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...